Homology Medicines, Inc. (FIXX): Price and Financial Metrics

Homology Medicines, Inc. (FIXX)

Today's Latest Price: $14.35 USD

0.07 (-0.49%)

Updated Nov 21 6:55pm

Add FIXX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

FIXX Stock Summary

  • Homology Medicines Inc's stock had its IPO on March 28, 2018, making it an older stock than merely 3.04% of US equities in our set.
  • For FIXX, its debt to operating expenses ratio is greater than that reported by just 0.39% of US equities we're observing.
  • FIXX's price/sales ratio is 213.38; that's higher than the P/S ratio of 98.79% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Homology Medicines Inc, a group of peers worth examining would be SNDX, CRNX, VCNX, ALPN, and FATE.
  • FIXX's SEC filings can be seen here. And to visit Homology Medicines Inc's official web site, go to www.homologymedicines.com.
FIXX Daily Price Range
FIXX 52-Week Price Range

FIXX Stock Price Chart More Charts

FIXX Price/Volume Stats

Current price $14.35
Prev. close $14.42
Day low $13.89
Day high $14.46
50-day MA $15.13
200-day MA $20.13
52-week high $31.80
52-week low $11.05
Volume 193,100
Avg. volume 239,105
Dividend yield N/A
Market Cap 631.90M

Homology Medicines, Inc. (FIXX) Company Bio

Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. The company was founded in 2015 and is based in Bedford, Massachusetts.

FIXX Latest News Stream

Event/Time News Detail
Loading, please wait...

FIXX Latest Social Stream

Loading social stream, please wait...

View Full FIXX Social Stream

FIXX Price Returns

1-mo 8.79%
3-mo -24.91%
6-mo -28.43%
1-year -26.75%
3-year N/A
5-year N/A
YTD -35.82%
2018 N/A
2017 N/A
2016 N/A
2015 N/A
2014 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5366 seconds.